Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 12/20 | 0.61 |
| ▸ | ACE | P12821 | 8/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 8/20 | 0.58 |
| ▸ | CPA1 | P15085 | 7/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958910 | 0.89 | ACE (0.58) | MMEACEACE2CPA1 | |
| SCHEMBL31430502 | 0.86 | GPR132 (0.47) | MMEACEACE2CPA1 | |
| SCHEMBL8469109 | 0.86 | MME (0.57) | MMEACEACE2CPA1NPSR1 | |
| SCHEMBL29539918 | 0.86 | ACE (0.54) | MMEACEACE2CPA1 | |
| Alanyl-Dl-Phenylalanine SCHEMBL4238049 | 0.81 | MME (0.65) | MMEACEACE2CPA1 | |
| Alanyl-Dl-Phenylalanine SCHEMBL28142228 | 0.81 | MME (0.65) | MMEACEACE2CPA1 | |
| Alanyl-Dl-Phenylalanine SCHEMBL28743188 | 0.81 | MME (0.65) | MMEACEACE2CPA1 | |
| Alanyl-Dl-Phenylalanine SCHEMBL893240 | 0.81 | MME (0.65) | MMEACEACE2CPA1 | |
| Alanyl-Dl-Phenylalanine SCHEMBL893241 | 0.81 | MME (0.65) | MMEACEACE2CPA1 | |
| Alanyl-Dl-Phenylalanine SCHEMBL28127119 | 0.81 | MME (0.65) | MMEACEACE2CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-10-24 | — | — | US | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| US-20240132558-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-04-25 | — | — | US | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| WO-2023288017-A2 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | MME 404/4885ACE 621/4885ACE2 1034/4885 |
| US-20240132558-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | MME 299/4885ACE 1219/4885ACE2 1269/4885 |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | MME 299/4885ACE 1219/4885ACE2 1269/4885 |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL17A | MME 638/4885ACE 1092/4885ACE2 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.